Labcyte Announces Collaboration with AstraZeneca
News Sep 25, 2013
Labcyte, who developed and commercialized acoustic liquid handling, recently developed techniques for the direct loading of samples into mass spectrometers. This capability creates the potential for high throughput, low cost, label-free analysis. AstraZeneca is supporting this development effort with the goal of expanding mass spectrometry-based analysis throughout the entire drug discovery and development process.
Mass spectrometry is used to quantify the amount of drug substance in screening assays, drug metabolism studies, and safety and efficacy experiments. The Labcyte Echo® acoustic liquid handling system uses sound waves to dispense a wide variety of liquids in nanoliter increments.
The development of an instrument that enables the delivery of test samples into a mass spectrometer through acoustic dispensing will generate better results with lower costs compared to traditional systems, which can be prone to transfer errors and sample contamination. It will streamline the process required to carry out these activities while increasing capacity to enable use in screening.
The drug discovery process requires continued advancement to generate greater biologically relevant data at lower costs and faster throughput. Data rich, label-free assays and broader phenotypic analyses are viewed as critical requirements to the future success of drug discovery programs. This trend requires novel techniques to meet these challenges. Mass spectrometry is an ideal candidate from a data perspective, but current throughput and cost per data point prevent the technology from being fully exploited. The goal of this collaboration is to overcome these limitations by enabling analysis of samples transferred directly from standard microplates with throughput significantly higher than current commercially available systems with substantially lower cost per data point.
“The potential for this breakthrough is yet another example of the incredible impact that acoustic dispensing is having in all areas of life sciences,” said Mark Fischer-Colbrie, Labcyte president and CEO. “Customers, including AstraZeneca, are using our acoustic liquid handling systems to discover new therapeutics, generate better diagnostic results or achieve personalized medical treatments. This work with AstraZeneca has the possibility to achieve dramatic improvements in measuring samples and experimental results. We are very excited to be working with one of the world’s leading pharmaceutical companies to pursue this major opportunity. It is a further testament to the unique capabilities of acoustic liquid handling.”
“The potential benefits of combining these technologies were originally identified by two of our Scientists,” said Mike Snowden, AstraZeneca VP Discovery Sciences. “We are excited to be working with Labcyte to develop acoustic dispensing for mass spectrometry. This project forms part of AstraZeneca’s efforts to access world-leading innovation to enhance the success of drug discovery. Combining acoustic delivery with mass spectrometry has the potential to open up new areas of science through transformational improvements in sampling rates and reductions in sampling volumes.”
Researchers Uncover Muscle Growth Inhibitor Activation Mechanism Aiding ALS Treatment EffortsNews
Researchers at the University of Cincinnati (UC) College of Medicine are part of an international team that has identified how the inactive or latent form of GDF8, a signaling protein also known as myostatin responsible for limiting muscle, is activated.READ MORE
New Research Could Significantly Accelerate Drug DiscoveryNews
Scientists have developed a suite of computer programs that cull through data on structure and genomic sequencing to identify the features that distinguish one enzyme from similar enzymes. This research has the potential to significantly accelerate drug discovery, allowing scientists to develop more effective drugs, more quickly.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.